Increasingdrug approval by regulatory authorities is projected to foster thegrowth of the Tourette syndrome treatment market. For example, inOctober 2017, Neurocrine Biosciences Inc. announced that the FoodDrug and Administration approved valbenazine orphan drug designationto deal with pediatric patients with Tourette syndrome. Also, anincreasing partnership among key players for developing newtreatments is again augmenting the growth of the market. For example,in September 2017, Teva Pharmaceutical Industries and NuvelutionPharma announced their partnership to produce AUSTEDO(deutetrabenazine) tablets for the treating tics which is related totourette syndrome in pediatric patients in the U.S. This partnershipwill drive the development of Austedo (deutetrabenazine) in Tourettesyndrome by bringing new treatments more quickly which are morerequired for the affected young patients.
NorthAmerica is anticipated to dominate the TouretteSyndrome Treatment Marketowing to the clear presence of a big number of key players such asAstraZeneca PLC, Otsuka Holdings Co., Ltd, and CatalystPharmaceutical Parteners, Inc. In line with the National Institute OfNeurological Disorders And Stroke(NIH), it's estimated that around2,00,000 Americans have the absolute most severe form of Tourettesyndrome and as many as one in 100 shows milder or fewer complexsymptoms such as vocal tics.
InMarch 2019, Wesley Medical Research partnered with the University ofSydney in Australia which carried the clinical trial to investigatewhether medical cannabis could be used to deal with individuals withTourette syndrome. This trial may help examine the efficacy andsafety of cannabinoids on tic frequency in addition to thepsychiatric symptoms related to Tourette syndrome.
InAugust 2019, Emalex Biosciences, Inc. (Emalex), announced that it hasreceived Fast Track designation because of its investigationalproduct, ecopipam, from the U.S. Food and Drug Administration (FDA)for the treating patients with Tourette Syndrome (TS).
Read More@https://bit.ly/3jjWJtZ
